EULAR Daily Recap: Day 3

4 months 2 weeks ago

ALTO: Long-term Outcomes of APIPPRA

4 months 2 weeks ago

Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA

Jiha Lee, MD

4 months 2 weeks ago

At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data,

Aurelie Najm AurelieRheumo

4 months 2 weeks ago

E3N cohort 78000+ women >30yrs follow up 698 incident RA cases) In non smokers, RA asso w/ -tall at birth HR=1.55 In smokers, RA risk associated w/ -prematurity HR=1.63 -in utero exposure to tobacco HR=1.83 (ns) #EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ

https://x.com/AurelieRheumo/status/1933566252582371485/photo/1

DMARD Combinations in RA Treatment

4 months 2 weeks ago

Dr. John Cush RheumNow

4 months 2 weeks ago

Late-Onset Disease: Different Age, Different Rules? We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/Txvr62UpWZ

Mrinalini Dey DrMiniDey

4 months 2 weeks ago

In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment? @RheumNow #EULAR2025 #OP0330

David Liew drdavidliew

4 months 2 weeks ago

Some RA-ILD is less of a worry, some is critical. How do we stratify? Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6. We need to do this more, so we can go really hard early when we need to. #EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2

https://x.com/drdavidliew/status/1933462421408264623/photo/1

David Liew drdavidliew

4 months 2 weeks ago

We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs: - lower inflamm - higher comorbidities Doesn’t necessarily map to fibromyalgia dx Beyond Rx, this is the critical question CareRA/2000 #EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb

Jiha Lee JihaRheum

4 months 2 weeks ago

Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025

David Liew drdavidliew

4 months 2 weeks ago

Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up? Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve

David Liew drdavidliew

4 months 2 weeks ago

Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

David Liew drdavidliew

4 months 2 weeks ago

@RheumNow So rheumatoid nodule treatment might target some of that pathophysiology. Rituximab, abatacept, or JAKi? And while surgery often isn’t great (plus they often grow back), definitely an option for some. Christopher Edwards #EULAR2025 @RheumNow https://t.co/sFWnQN8uC4